Literature DB >> 23819906

Antifibrotic role of chemokine CXCL9 in experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats.

Jiaqing Shen1, Jing Gao, Congying Chen, Huili Lu, Guoyong Hu, Jie Shen, Shunying Zhu, Mingyuan Wu, Xia Wang, Lan Qian, Yan Yu, Wei Han, Rong Wan, Xingpeng Wang.   

Abstract

Chemokines have been shown to play an important role in the pathogenesis of pancreatitis, but the role of chemokine CXCL9 in pancreatitis is poorly understood. The aim of this study was to investigate whether CXCL9 was a modulating factor in chronic pancreatitis. Chronic pancreatitis was induced in Sprague-Dawley rats by intraductal infusion of trinitrobenzene sulfonic acid (TNBS) and CXCL9 expression was assessed by immunohistochemistry, Western blot analysis and enzyme linked immunosorbent assay (ELISA). Recombinant human CXCL9 protein (rCXCL9), neutralizing antibody and normal saline (NS) were administered to rats with chronic pancreatitis by subcutaneous injection. The severity of fibrosis was determined by measuring hydroxyproline in pancreatic tissues and histological grading. The effect of rCXCL9 on activated pancreatic stellate cells (PSCs) in vitro was examined and collagen 1α1, TGF-β1 and CXCR3 expression was assessed by Western blot analysis in isolated rat PSCs. Chronic pancreatic injury in rats was induced after TNBS treatment and CXCL9 protein was markedly upregulated during TNBS-induced chronic pancreatitis. Although parenchymal injury in the pancreas was not obviously affected after rCXCL9 and neutralizing antibody administration, rCXCL9 could attenuate fibrogenesis in TNBS-induced chronic pancreatitis in vivo and exerted antifibrotic effects in vitro, suppressing collagen production in activated PSCs. In conclusion, CXCL9 is involved in the modulation of pancreatic fibrogenesis in TNBS-induced chronic pancreatitis in rats, and may be a therapeutic target in pancreatic fibrosis.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CXCL9; Chronic pancreatitis; Fibrosis; Pancreatic stellate cells (PSCs); Rats

Mesh:

Substances:

Year:  2013        PMID: 23819906     DOI: 10.1016/j.cyto.2013.05.012

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

Review 1.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

2.  Ageing is associated with molecular signatures of inflammation and type 2 diabetes in rat pancreatic islets.

Authors:  Ionel Sandovici; Constanze M Hammerle; Wendy N Cooper; Noel H Smith; Jane L Tarry-Adkins; Benjamin J Dunmore; Julien Bauer; Simon R Andrews; Giles S H Yeo; Susan E Ozanne; Miguel Constância
Journal:  Diabetologia       Date:  2015-12-23       Impact factor: 10.122

Review 3.  Pancreatic stellate cell: Pandora's box for pancreatic disease biology.

Authors:  Ratnakar R Bynigeri; Aparna Jakkampudi; Ramaiah Jangala; Chivukula Subramanyam; Mitnala Sasikala; G Venkat Rao; D Nageshwar Reddy; Rupjyoti Talukdar
Journal:  World J Gastroenterol       Date:  2017-01-21       Impact factor: 5.742

4.  A network-based method using a random walk with restart algorithm and screening tests to identify novel genes associated with Menière's disease.

Authors:  Lin Li; YanShu Wang; Lifeng An; XiangYin Kong; Tao Huang
Journal:  PLoS One       Date:  2017-08-07       Impact factor: 3.240

5.  Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases.

Authors:  Morgan K Groover; Jillian M Richmond
Journal:  F1000Res       Date:  2020-10-05

Review 6.  Molecular mechanisms of pancreatic myofibroblast activation in chronic pancreatitis and pancreatic ductal adenocarcinoma.

Authors:  Andrew Cannon; Christopher Michael Thompson; Rakesh Bhatia; Katharine Anne Armstrong; Joyce Christopher Solheim; Sushil Kumar; Surinder Kumar Batra
Journal:  J Gastroenterol       Date:  2021-07-19       Impact factor: 6.772

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.